SCHEMBL649921

SCHEMBL649921

C=CCN(CC=O)C(=O)OCC

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
MAPT P10636 2/20 0.38
HCAR2 Q8TDS4 1/20 0.34
TRPM8 Q7Z2W7 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
LMNA P02545 1/20 0.32
HSD17B10 Q99714 1/20 0.32
ALOX5 P09917 1/20 0.32
ALOX15 P16050 1/20 0.31
MGAM O43451 1/20 0.31
GAA P10253 1/20 0.31
SI P14410 1/20 0.31
MGAM2 Q2M2H8 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
SOAT1 P35610 1/20 0.31
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
POLB P06746 1/20 0.31
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7023419 0.92 ALDH1A1 (0.48) ALDH1A1MAPTHCAR2TRPM8SMN1; SMN2
Methyl Alcohol SCHEMBL11376423 0.90 ALDH1A1 (0.47) ALDH1A1MAPTHCAR2TRPM8SMN1; SMN2
SCHEMBL23532412 0.83 ALDH1A1 (0.39) ALDH1A1MAPTSMN1; SMN2HSD17B10
SCHEMBL29021084 0.81 ALDH1A1 (0.42) ALDH1A1MAPTHCAR2TRPM8SMN1; SMN2
SCHEMBL8142578 0.81 ALDH1A1 (0.41) ALDH1A1MAPTSMN1; SMN2LMNANPSR1
SCHEMBL1077649 0.80 ALDH1A1 (0.46) ALDH1A1MAPTHCAR2SMN1; SMN2LMNA
SCHEMBL8741050 0.80 MAPT (0.35) ALDH1A1MAPTLMNAHSD17B10ALOX15
SCHEMBL9473559 0.80 ALDH1A1 (0.41) ALDH1A1MAPTHCAR2TRPM8SMN1; SMN2
SCHEMBL6210893 0.80 ALDH1A1 (0.35) ALDH1A1MAPTLMNAHSD17B10ALOX15
SCHEMBL11601068 0.80 ALDH1A1 (0.41) ALDH1A1MAPTHCAR2TRPM8SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12465590-B2 Oxalamido-substituted tricyclic inhibitors of hepatitis b virus OSPEDALE SAN RAFFAELE S.R.L. (IT) 2025-11-11 US disclosed
CN-119409710-A Oxamide substituted hepatitis b virus tricyclic inhibitors 圣拉斐尔医院有限公司 2025-02-11 CN disclosed
US-20240425476-A1 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS ASTRAZENECA AB (SE) 2024-12-26 US disclosed
CN-114555608-B Oxamide substituted hepatitis b virus tricyclic inhibitors 圣拉斐尔医院有限公司 2024-11-01 CN disclosed
EP-3833672-B1 TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS OSPEDALE SAN RAFFAELE SRL (IT) 2024-09-18 EP disclosed
US-20240182441-A1 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS ASTRAZENECA AB (SE) 2024-06-06 US disclosed
CN-113272309-B Tricyclic inhibitors of hepatitis b virus 圣拉斐尔医院有限公司 2024-02-23 CN disclosed
CN-109928971-B Aryl substituted aminotetrahydropyrans and uses thereof 广东东阳光药业股份有限公司 2024-01-16 CN disclosed
US-20230076319-A1 INHIBITORS OF HEPATITIS B VIRUS ANTIOS THERAPEUTICS INC (US) 2023-03-09 US disclosed
EP-4119551-A1 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS Astrazeneca AB (SE) 2023-01-18 EP disclosed
WO-2001081347-A2 DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS ABBOTT LABORATORIES (US) 2001-11-01 WO disclosed
WO-2001058871-A1 PIPERIDYL CARBOXYLIC ACIDS AS INTEGRIN ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2001-08-16 WO disclosed
EP-1122257-A1 Benzimidazole compounds as ORL1-receptor agonists PFIZER INC. (US) 2001-08-08 EP disclosed
US-5607942-A BACTERICIDES BAYER AKTIENGESELLSCHAFT (DE) 1997-03-04 US disclosed
US-5416096-A 7-(1-pyrrolidinyl)-3-quinolone carboxylic acid derivatives as antibacterial agents and feed additives BAYER AKTIENGESELLSCHAFT (DE) 1995-05-16 US disclosed
US-5241076-A 1,4-diazatricyclo [6.3.0.0]undecanes BAYER AKTIENGESELLSCHAFT (DE) 1993-08-31 US disclosed
US-5177210-A Preparation of 2,7-diazabicyclo(3.3.0)octanes BAYER AKTIENGESELLSCHAFT (DE) 1993-01-05 US disclosed
US-5071999-A Preparation of 2,7-diazabicyclo[3.3.0]octanes BAYER AKTIENGESELLSCHAFT (DE) 1991-12-10 US disclosed
US-5059597-A Animal growth regulators; enterobacter BAYER AKTIENGESELLSCHAFT (DE) 1991-10-22 US disclosed
US-4990517-A 7-(1-pyrrolidinyl)-3-quinolone- and -naphthyridonecarboxylic acid derivatives as antibacterial agents and feed additives BAYER AKTIENGESELLSCHAFT (DE) 1991-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12465590-B2 Oxalamido-substituted tricyclic inhibitors of hepatitis b virus OAT, SLC10A1, OTC ALDH1A1 1116/4885MAPT 2805/4885HCAR2 2062/4885
US-20240425476-A1 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS EGFR, ERBB2, ERBB3 ALDH1A1 2153/4885MAPT 4309/4885HCAR2 2523/4885
US-20230076319-A1 INHIBITORS OF HEPATITIS B VIRUS HAVCR2, HDGF, SLC10A1 ALDH1A1 1035/4885MAPT 3651/4885HCAR2 1382/4885
US-20240182441-A1 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS EGFR, ERBB2, ERBB3 ALDH1A1 2153/4885MAPT 4309/4885HCAR2 2523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.